Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

AstraZeneca's experimental pill camizestrant, when administered at the first sign of resistance to standard treatments for hormone receptor-positive, HER2-negative breast cancer, reduced the risk of disease progression or death by 56% according to a trial presented at ASCO. The study utilized a liquid biopsy to detect early drug resistance (ESR1 mutations) and prompted an early switch to camizestrant plus a CDK4/6 inhibitor, resulting in a statistically significant 16-month progression-free survival compared to 9.2 months with standard therapy; additionally, AstraZeneca's durvalumab combined with chemotherapy showed a 29% improvement in event-free survival for early-stage stomach and esophageal cancers.

Analysis

AstraZeneca has presented highly positive clinical trial results for two key oncology assets, camizestrant and durvalumab, at the American Society of Clinical Oncology meeting, with both studies concurrently published in the New England Journal of Medicine, signaling significant potential advancements in cancer treatment. For its experimental pill camizestrant, targeting hormone receptor-positive, HER2-negative breast cancer, a trial demonstrated a 56% reduction in the risk of disease progression or death when administered following early detection of ESR1 mutations via liquid biopsy, indicating resistance to standard treatments. Patients switched to camizestrant plus a CDK4/6 inhibitor achieved a median progression-free survival of 16 months, a statistically significant improvement over the 9.2 months observed in patients continuing standard therapy plus placebo, with no new side effects reported. This innovative approach, utilizing liquid biopsies for early intervention, is viewed by oncology experts as potentially paradigm-shifting given that approximately 40% of patients on standard aromatase inhibitors develop such resistance mutations. Separately, AstraZeneca's immunotherapy durvalumab (Imfinzi), when combined with FLOT chemotherapy for early-stage stomach and esophageal cancers in a study of nearly 950 patients, improved event-free survival by 29% compared to chemotherapy alone, also without new safety signals and is anticipated to alter current clinical practice. These robust findings underscore AstraZeneca's strengthening oncology pipeline and its potential to address unmet needs and expand its market presence in these cancer types.

Key Decisions for Investors

• Investors should recognize these strong clinical trial outcomes for camizestrant and durvalumab as significant positive catalysts for AstraZeneca, likely enhancing its oncology franchise's growth prospects and future revenue potential.
• Consider the competitive implications of camizestrant's success in HR-positive, HER2-negative breast cancer, as its potential adoption following early resistance detection could impact the market share of existing CDK4/6 inhibitors from companies like Novartis, Pfizer, and Lilly.
• Monitor upcoming regulatory submissions and decisions for both camizestrant and durvalumab, as approvals would be critical milestones for commercialization and realizing the substantial market opportunities suggested by these compelling trial results.